Shares of Sanofi (NASDAQ:SNY - Get Free Report) have been assigned an average rating of "Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $63.33.
SNY has been the topic of a number of analyst reports. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. BNP Paribas began coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th.
Check Out Our Latest Research Report on Sanofi
Sanofi Stock Performance
Shares of SNY opened at $49.98 on Friday. The business has a 50-day simple moving average of $54.22 and a two-hundred day simple moving average of $52.00. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The stock has a market cap of $126.26 billion, a price-to-earnings ratio of 20.07, a PEG ratio of 1.01 and a beta of 0.55.
Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The company had revenue of $10.41 billion for the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm's revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.78 EPS. On average, analysts expect that Sanofi will post 4.36 EPS for the current year.
Sanofi Increases Dividend
The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a $2.0369 dividend. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. This represents a yield of 3.1%. Sanofi's payout ratio is presently 57.14%.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the company. Barclays PLC lifted its position in Sanofi by 107.5% during the third quarter. Barclays PLC now owns 639,772 shares of the company's stock valued at $36,869,000 after purchasing an additional 331,445 shares during the last quarter. Tidal Investments LLC grew its position in Sanofi by 126.7% in the third quarter. Tidal Investments LLC now owns 13,798 shares of the company's stock worth $795,000 after acquiring an additional 7,711 shares in the last quarter. ORG Partners LLC grew its position in Sanofi by 17.7% in the fourth quarter. ORG Partners LLC now owns 1,681 shares of the company's stock worth $81,000 after acquiring an additional 253 shares in the last quarter. ST Germain D J Co. Inc. increased its stake in Sanofi by 9.0% during the fourth quarter. ST Germain D J Co. Inc. now owns 8,060 shares of the company's stock worth $389,000 after acquiring an additional 665 shares during the last quarter. Finally, Thomasville National Bank raised its position in Sanofi by 1.6% during the fourth quarter. Thomasville National Bank now owns 80,101 shares of the company's stock valued at $3,863,000 after purchasing an additional 1,265 shares during the period. 14.04% of the stock is currently owned by institutional investors.
Sanofi Company Profile
(
Get Free ReportSanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
